Een celpenetrerend CD40-TRAF2,3-blokkerend peptide vermindert ontsteking en neuronaal verlies na ischemie/reperfusie
Terwijl de toediening van anti-CD154 mAbs bij muizen de CD40-CD154-route valideerde als een doelwit tegen ontstekingsaandoeningen, veroorzaakte deze benadering trombo-embolie bij mensen (niet gerelateerd aan CD40-remming) en wordt verwacht dat het vatbaar maakt voor opportunistische infecties. Er is behoefte aan alternatieve benaderingen om CD40 te remmen die deze complicaties vermijden . CD40-signalen through TRAF2,3- en TRAF6-bindingsplaatsen. Aangezien CD40-TRAF6 de route is die de respons stimuleert voor celgemedieerde immuniteit tegen opportunistische pathogenen, onderzochten we de effecten van farmacologische remming van CD40-TRAF2,3-signalering.
We gebruikten een mannequin van ischemie/reperfusie (I/R)-geïnduceerde retinopathie, een door CD40 aangestuurde inflammatoire aandoening. Intravitreale toediening van een celpenetrerend CD40-TRAF2,3-blokkerend peptide verminderde ICAM-1-upregulatie in retinale endotheelcellen en CXCL1-upregulatie in endotheel- en Müller-cellen. Het peptide verminderde infiltratie van leukocyten, opregulatie van NOS2/COX-2/TNF-NF/IL-1β en verbeterde neuronaal verlies, effecten die lijken op die waargenomen na I/R in Cd40-/- muizen. Terwijl een celpenetrerend CD40-TRAF6-blokkerend peptide ook I/R-geïnduceerde ontsteking verminderde, dit peptide (maar niet het CD40-TRAF2,3-blokkerende peptide) verminderde de controle van de opportunistische pathogeen Toxoplasma gondii in het netvlies. Remming van de CD40-TRAF2,3-route is dus een nieuwe en krachtige benadering om CD40-geïnduceerde ontsteking te verminderen, terwijl waarschijnlijk het risico op opportunistische infecties wordt verminderd die anders gepaard zouden gaan met CD40-remming.
Een blokkerend peptide stabiliseert lysofosfatidinezuurreceptor 1 en bevordert door lysofosfatidinezuur geïnduceerde cellulaire reacties
- G-eiwit-gekoppelde receptoren reguleren een verscheidenheid aan cellulaire reacties en zijn beschouwd als therapeutische doelen voor menselijke ziekten. Lysofosfatidinezuurreceptor 1 (LPA1) is een receptor voor bioactief lysofosfolipide, LPA. LPA/LPA1-gemedieerde signalering draagt bij aan ontstekings- en fibrotische reacties bij longziekten; dus het begrijpen van de regulering van LPA1-stabiliteit is belangrijk voor het moduleren van LPA / LPA1-signalering.
- Onze eerdere studie heeft aangetoond dat LPA1 wordt afgebroken in het Nedd4-achtige (Nedd4L) E3-ubiquitine-ligase-gemedieerde ubiquitine-proteasoomsysteem. In de huidige studie proberen we een peptide te identificeren dat LPA1 stabiliseert door de LPA1-associatie met Nedd4L te verstoren. LPA-behandeling induceert zowel endogene als tot overexpressie gebrachte LPA1-afbraak , die wordt verzwakt door een proteasoomremmer, wat suggereert dat LPA1 in het proteasoom wordt afgebroken. LPA verhoogt de fosforylering van extracellulair signaal-gereguleerd kinase half of (Erk1/2) en I-KB-kinase in longepitheelcellen, en dit impact wordt bevorderd door overexpressie van een peptide (P1) dat de C-terminus van LPA1 nabootst. P1, geen controlepeptide, verzwakt door LPA geïnduceerde ubiquitinatie en afbraak van LPA1, wat suggereert dat P1 LPA1 stabiliseert.
- Verder vermindert P1 de door Nedd4L gemedieerde afbraak van de associatie van LPA1 en Nedd4L/LPA1. Naast het verhogen van LPA1-signalering, verbetert P1 de door LPA geïnduceerde celmigratie en genexpressie van Elafin, matrix metallopeptidase 1 en serpin-familie B-lid 2 in longepitheelcellen. Deze gegevens suggereren dat verstoring van LPA1-interactie met Nedd4L door P1 de LPA1-stabiliteit en LPA/LPA1-signalering verhoogt.
Functieblokkerende RHAMM-peptiden verzwakken fibrose en bevorderen antifibrotische adipokines in een door bleomycine geïnduceerd muizenmodel van systemische sclerose
Systemische sclerose (SSc) is een chronische, fibrotische aandoening die gepaard gaat met een hoge ziektespecifieke mortaliteit en morbiditeit. Cutane manifestaties omvatten huidverdikking en vernietiging van huidvetweefsel. Accumulatie van hyaluronan met een laag molecuulgewicht, dat signalen geeft through RHAMM (Receptor for Hyaluronan Mediated Motility), leidt tot progressieve fibrose en is gecorreleerd met een verhoogde ernst van SSc. Het doel van deze studie is om de werkzaamheid te testen van twee functieblokkerende RHAMM-peptiden, NPI-110 en NPI-106, bij het verminderen van huidfibrose in een door bleomycine geïnduceerd muismodel van systemische sclerose.
NPI-110 verminderde zichtbare metingen van fibrose (dermale dikte, collageenproductie, afzetting en organisatie) en pro-fibrotische genexpressie (Tgfb1, c-Myc, Col1a1, Col3a1). Behandeling met NPI-110 verhoogde ook de expressie van de antifibrotische adipokines perilipine en adiponectine. Beide RHAMM-peptiden verminderden de dermale RHAMM-expressie sterk, wat voorspelt dat dermale fibroblasten peptide-targets zijn. Transcriptoom- en celcultuuranalyses met behulp van Rhamm-/- en Rhamm-gereddermale fibroblasten onthullen een TGFB1/RHAMM/MYC-signaleringsas die fibrogene genexpressie en myofibroblastdifferentiatie bevordert. RHAMM functieblokkerende peptiden onderdrukken deze signalering en voorkomen door TGFB1 geïnduceerde myofibroblastdifferentiatie. Deze resultaten suggereren dat het remmen van RHAMM-signalering een nieuwe behandelingsmethode zal bieden voor cutane fibrose bij systemische sclerose.
Kunitz-type peptiden van de zeeanemoon Heteractis crispa demonstreren kaliumkanaalblokkering en ontstekingsremmende activiteiten
De Kunitz/BPTI-peptidefamilie omvat unieke vertegenwoordigers die verschillende biologische activiteiten aantonen. Elektrofysiologische screening van peptiden HCRG1 en HCRG2 van de zeeanemoon Heteractis crispa op zes Kv1.x kanaal-isovormen en insecten Shaker IR-kanaal tot expressie gebracht in Xenopus laevis oöcyten onthulden hun kaliumkanalen blokkerende activiteit. HCRG1 en HCRG2 lijken de eerste Kunitz-type peptiden uit zee anemonen blokkeren Kv1.Three met IC zijn 50 40,7 en 29,7 nM. Bovendien variëren peptiden voornamelijk in bindingsaffiniteit voor de Kvl.2-kanalen.
Er werd vastgesteld dat de enkele substitutie, Ser5Leu, in de TRPV1-kanaalantagonist, HCRG21, een zwakke blokkerende activiteit van Kv1.1, Kv1.2 en Kv1.Three induceert. Blijkbaar, voor de affiniteit en selectiviteit van Kunitz-voudige toxines voor Kv1.x-isovormen, het aantal en de verdeling over hun moleculen van geladen, hydrofobe en polaire ongeladen residuen, evenals de aard van het kanaalresidu op positie 379 (Tyr, Val of His) zijn belangrijk.
Het testen van de verbindingen in een mannequin van acute lokale ontsteking veroorzaakt door de introductie van carrageenantoediening in de poten van muizen, onthulde dat HCRG1 in doses van 0,1-1 mg/kg het quantity van zich ontwikkelend oedeem gedurende 24 uur verminderde, vergelijkbaar met het impact van de niet-steroïde anti- -ontstekingsmedicijn, indomethacine, in een dosis van 5 mg/kg. ELISA-analyse van het bloed van dieren toonde aan dat het peptide de synthese van TNF-α verminderde, een pro-inflammatoire mediator die een leidende rol speelt bij de ontwikkeling van oedeem in dit mannequin.
CD47/SIRPα blokkerende peptide-identificatie en synergetisch impact met bestraling voor kankerimmunotherapie
Achtergrond: Immunotherapie heeft opmerkelijke vooruitgang geboekt through een verscheidenheid aan strategieën tegen tumorcellen die immuunsurveillance ontwijken. Als belangrijke aangeboren immuuncellen spelen macrofagen een belangrijke rol bij het handhaven van de homeostase, het voorkomen van pathogene invasie, het weerstaan van tumorcellen en het bevorderen van een adaptieve immuunrespons. CD47 blijkt tot overexpressie te worden gebracht op tumorcellen en werkt als een eet-me-niet-signaal, wat bijdraagt aan het ontwijken van het immuunsysteem. Macrofagen gemedieerde fagocytose through blokkade CD47/SIRPα (signaalregulerend eiwit alfa) interactie bleek een effectieve antitumor immuunrespons te induceren.
Methoden: Een nieuw peptide pep-20, specifiek gericht op CD47 en het blokkeren van CD47/SIRPα-interactie, werd geïdentificeerd through bio-panning van faagdisplaybibliotheek met hoge doorvoer. Het vermogen om de macrofaag-gemedieerde fagocytose-activiteiten en antitumoreffecten van pep-20 te verbeteren, werd onderzocht. Het mechanisme van pep-20 om T-celrespons te induceren werd onderzocht door ex vivo analyse en bevestigd through macrofaag uitputtende strategie. De structuur-activiteitsrelatie en D-aminozuursubstitutie van pep-20 werden ook bestudeerd. De antitumoreffecten en het mechanisme van een proteolyseresistent D-aminozuurderivaat pep-20-D12 in combinatie met bestraling (IR) werden ook onderzocht.
Resultaten: Pep-20 vertoonde een opmerkelijke verbetering van macrofaag-gemedieerde fagocytose van zowel vaste als hematologische tumorcellen in vitro, en remde tumorgroei in immuuncompetente tumordragende muizen. Bovendien bevorderde pep-20 macrofagen om de antitumor-T-celrespons te mobiliseren met minimale toxiciteit. Bovendien toonde systemische toediening van het derivaat pep-20-D12 een robuuste synergetische antitumorwerking in combinatie met IR.
Conclusie: Samengevat toonden deze resultaten aan dat CD47/SIRPα-blokkerende peptiden, pep-20 en zijn derivaat, zouden kunnen dienen als veelbelovende kandidaten om macrofagen-gemedieerde fagocytose en immuunrespons bij kankerimmunotherapie te bevorderen.
) Anti-XTP4 (3B5) |
|||
| YF-MA19537 | Abfrontier | 100 ug | EUR 363 |
|
Description: Mouse monoclonal to XTP4 |
|||
) Human XTP4 Antibody (Biotin Conjugate) |
|||
| 33080-05121 | AssayPro | 150 ug | EUR 369 |
 Substance P reversed sequence Peptide |
|||
| 20-abx266314 | Abbexa |
|
|
|
|||
 Erythropoietin Mimetic Peptide Sequence 20 |
|||
| H-4344.0001 | Bachem | 1.0mg | EUR 454 |
|
Description: Sum Formula: C72H99N17O17S2; CAS# [203397-62-0] net |
|||
|
Erythropoietin Mimetic Peptide Sequence 20 |
|||
| H-4344.0005 | Bachem | 5.0mg | EUR 1723 |
|
Description: Sum Formula: C72H99N17O17S2; CAS# [203397-62-0] net |
|||
5 peptide (repeat-sequence peptide of the P. falciparum circumsporozoite protein, CSP) control/blocking peptide) (NANP)5 peptide (repeat-sequence peptide of the P. falciparum circumsporozoite protein, CSP) control/blocking peptide |
|||
| NANP51-P | Alpha Diagnostics | 1 mg | EUR 347 |
3 peptide (repeat-sequence peptide of the P. berghei circumsporozoite protein, CSP) control/blocking peptide) (PPPPNAND)3 peptide (repeat-sequence peptide of the P. berghei circumsporozoite protein, CSP) control/blocking peptide |
|||
| PPPP321-P | Alpha Diagnostics | 100 ug | EUR 164 |
) Human XTP4 AssayLite Antibody (FITC Conjugate) |
|||
| 33080-05141 | AssayPro | 150 ug | EUR 428 |
) Human XTP4 AssayLite Antibody (RPE Conjugate) |
|||
| 33080-05151 | AssayPro | 150 ug | EUR 428 |
) Human XTP4 AssayLite Antibody (APC Conjugate) |
|||
| 33080-05161 | AssayPro | 150 ug | EUR 428 |
) Human XTP4 AssayLite Antibody (PerCP Conjugate) |
|||
| 33080-05171 | AssayPro | 150 ug | EUR 471 |
4 peptide (minor repeat-sequence peptide of the P. falciparum circumsporozoite protein, CSP) control/blocking peptide) (NVDP)4 peptide (minor repeat-sequence peptide of the P. falciparum circumsporozoite protein, CSP) control/blocking peptide |
|||
| NVDP41-P | Alpha Diagnostics | 100 ug | EUR 164 |
3 (repeat-sequence peptide of the P. vivax circumsporozoite protein, CSP) control/blocking peptide) (DRAAGQPAG)3 (repeat-sequence peptide of the P. vivax circumsporozoite protein, CSP) control/blocking peptide |
|||
| DRAA31-P | Alpha Diagnostics | 100 ug | EUR 164 |
 matrix protein 2 hybrid sequence Control/blocking peptide) Influenza A virus (H5N1) matrix protein 2 hybrid sequence Control/blocking peptide |
|||
| M2E11-P | Alpha Diagnostics | 100 ug | EUR 164 |
 C-Peptide Blocking Peptide |
|||
| 3277BP-50 | Biovision | EUR 153 | |
 BAK1 Blocking Peptide |
|||
| 3031BP-50 | Biovision | EUR 153 | |
 Bax Blocking Peptide |
|||
| 3032BP-50 | Biovision | EUR 153 | |
 p53 Blocking Peptide |
|||
| 3036RBP-50 | Biovision | EUR 153 | |
 RAIDD Blocking Peptide |
|||
| 3037BP-50 | Biovision | EUR 153 | |
 NFkB Blocking Peptide |
|||
| 3038BP-50 | Biovision | EUR 153 | |
 FADD Blocking Peptide |
|||
| 3039BP-50 | Biovision | EUR 153 | |
 PBR Blocking Peptide |
|||
| 3044BP-50 | Biovision | EUR 153 | |
 MBD4 Blocking Peptide |
|||
| 3056BP-50 | Biovision | EUR 153 | |
 PRMT7 blocking peptide |
|||
| 3059BP-50 | Biovision | EUR 153 | |
 DR4 Blocking Peptide |
|||
| 3061BP-50 | Biovision | EUR 153 | |
 DR5 Blocking Peptide |
|||
| 3062BP-50 | Biovision | EUR 153 | |
 CD40 Blocking Peptide |
|||
| 3072BP-50 | Biovision | EUR 153 | |
 Calreticulin Blocking Peptide |
|||
| 3077BP-50 | Biovision | EUR 153 | |
 PRMT6 Blocking Peptide |
|||
| 3086BP-50 | Biovision | EUR 153 | |
 TCTN1 Blocking Peptide |
|||
| 3087BP-50 | Biovision | EUR 153 | |
|
TCTN1 Blocking Peptide |
|||
| 3088BP-50 | Biovision | EUR 153 | |
 KLF4 Blocking Peptide |
|||
| 3089BP-50 | Biovision | EUR 153 | |
 Lin28 Blocking Peptide |
|||
| 3091BP-50 | Biovision | EUR 153 | |
 Hsp27 Blocking Peptide |
|||
| 3093BP-50 | Biovision | EUR 153 | |
 Hsp60 Blocking Peptide |
|||
| 3094RBP-50 | Biovision | EUR 153 | |
 Hsc70 Blocking Peptide |
|||
| 3095BP-50 | Biovision | EUR 153 | |
 Hsp70 Blocking Peptide |
|||
| 3097BP-50 | Biovision | EUR 153 | |
 SIRT7 Blocking Peptide |
|||
| 3099BP-50 | Biovision | EUR 153 | |
 AT2 Blocking Peptide |
|||
| 30R-AA024 | Fitzgerald | 100 ug | EUR 241 |
|
Description: A synthetic AT2 Blocking peptide for use as a blocking control in assays to test for specificity of AT2 antibody, catalog no. 70R-AR006 |
|||
 UCP3 Blocking Peptide |
|||
| 30R-AU006 | Fitzgerald | 100 ug | EUR 241 |
|
Description: A synthetic UCP3 Blocking peptide for use as a blocking control in assays to test for specificity of UCP3 antibody, catalog no. 20R-UR003 |
|||
 PKA Blocking Peptide |
|||
| 3115BP-50 | Biovision | EUR 153 | |
 Raf1 Blocking Peptide |
|||
| 3116BP-50 | Biovision | EUR 153 | |
 Wee1 Blocking Peptide |
|||
| 3120BP-50 | Biovision | EUR 153 | |
 Stat1 Blocking Peptide |
|||
| 3133RBP-50 | Biovision | EUR 153 | |
 MAK10 Blocking Peptide |
|||
| 3134BP-50 | Biovision | EUR 153 | |
 ACADM Blocking Peptide |
|||
| 3137BP-50 | Biovision | EUR 153 | |
 ACADL Blocking Peptide |
|||
| 3139BP-50 | Biovision | EUR 153 | |
 ACADSB Blocking Peptide |
|||
| 3150BP-50 | Biovision | EUR 153 | |
|
ACADSB Blocking Peptide |
|||
| 3157BP-50 | Biovision | EUR 153 | |
 Survivin Blocking Peptide |
|||
| 3160BP-50 | Biovision | EUR 153 | |
 TXNRD1 Blocking Peptide |
|||
| 7005BP-50 | Biovision | EUR 153 | |
 EDEM2 Blocking Peptide |
|||
| 6633BP-50 | Biovision | EUR 153 | |
 SPHKAP Blocking Peptide |
|||
| 6656BP-50 | Biovision | EUR 153 | |
 USP8 Blocking Peptide |
|||
| 6658BP-50 | Biovision | EUR 153 | |
 EHHADH Blocking Peptide |
|||
| 6678BP-50 | Biovision | EUR 153 | |
 ACTH Blocking Peptide |
|||
| A1051BP-50 | Biovision | EUR 153 | |
 Secretin Blocking Peptide |
|||
| A1054BP-50 | Biovision | EUR 153 | |
 C16orf73 Blocking Peptide |
|||
| 33R-1811 | Fitzgerald | 100 ug | EUR 180 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of C16orf73 antibody, catalog no. 70R-4561 |
|||
 ITGBL1 Blocking Peptide |
|||
| 33R-1812 | Fitzgerald | 100 ug | EUR 180 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of ITGBL1 antibody, catalog no. 70R-1700 |
|||
 C6ORF21 Blocking Peptide |
|||
| 33R-1813 | Fitzgerald | 100 ug | EUR 180 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of C6orf21 antibody, catalog no. 70R-1743 |
|||
 PNPLA3 Blocking Peptide |
|||
| 33R-1814 | Fitzgerald | 100 ug | EUR 180 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of PNPLA3 antibody, catalog no. 70R-2371 |
|||
 SERPINF2 Blocking Peptide |
|||
| 33R-1815 | Fitzgerald | 100 ug | EUR 180 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of SERPINF2 antibody, catalog no. 70R-9700 |
|||
 SLC22A16 Blocking Peptide |
|||
| 33R-1816 | Fitzgerald | 100 ug | EUR 180 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of SLC22A16 antibody, catalog no. 70R-1824 |
|||
 MYLIP Blocking Peptide |
|||
| 33R-1817 | Fitzgerald | 100 ug | EUR 180 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of MYLIP antibody, catalog no. 70R-2736 |
|||
 PBEF1 Blocking Peptide |
|||
| 33R-1818 | Fitzgerald | 100 ug | EUR 180 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of PBEF1 antibody, catalog no. 70R-1027 |
|||
 WNT9B Blocking Peptide |
|||
| 33R-1820 | Fitzgerald | 100 ug | EUR 180 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of WNT9B antibody, catalog no. 70R-7246 |
|||
 TM4SF4 Blocking Peptide |
|||
| 33R-1822 | Fitzgerald | 100 ug | EUR 180 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of TM4SF4 antibody, catalog no. 70R-7470 |
|||
 ZNF550 Blocking Peptide |
|||
| 33R-1823 | Fitzgerald | 100 ug | EUR 180 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of ZNF550 antibody, catalog no. 20R-1242 |
|||
 SHROOM2 Blocking Peptide |
|||
| 33R-1824 | Fitzgerald | 100 ug | EUR 180 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of SHROOM2 antibody, catalog no. 70R-5079 |
|||
 LOC441964 Blocking Peptide |
|||
| 33R-1825 | Fitzgerald | 100 ug | EUR 180 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of LOC441964 antibody, catalog no. 70R-1024 |
|||
 ADRB1 Blocking Peptide |
|||
| 33R-1826 | Fitzgerald | 100 ug | EUR 180 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of ADRB1 antibody, catalog no. 70R-5939 |
|||
 TCP11 Blocking Peptide |
|||
| 33R-1827 | Fitzgerald | 100 ug | EUR 180 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of TCP11 antibody, catalog no. 70R-3950 |
|||
 KIF2B Blocking Peptide |
|||
| 33R-1828 | Fitzgerald | 100 ug | EUR 180 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of KIF2B antibody, catalog no. 70R-5498 |
|||
 RBJ Blocking Peptide |
|||
| 33R-1829 | Fitzgerald | 100 ug | EUR 180 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of RBJ antibody, catalog no. 70R-5875 |
|||
 MFI2 Blocking Peptide |
|||
| 33R-1830 | Fitzgerald | 100 ug | EUR 180 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of MFI2 antibody, catalog no. 70R-10040 |
|||
 UNC84B Blocking Peptide |
|||
| 33R-1831 | Fitzgerald | 100 ug | EUR 180 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of UNC84B antibody, catalog no. 70R-6991 |
|||
 CLEC4M Blocking Peptide |
|||
| 33R-1832 | Fitzgerald | 100 ug | EUR 180 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of CLEC4M antibody, catalog no. 70R-8545 |
|||
 LAYN Blocking Peptide |
|||
| 33R-1833 | Fitzgerald | 100 ug | EUR 180 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of LAYN antibody, catalog no. 70R-7484 |
|||
 FKBP5 Blocking Peptide |
|||
| 33R-1834 | Fitzgerald | 100 ug | EUR 180 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of FKBP5 antibody, catalog no. 70R-2377 |
|||
 GJB6 Blocking Peptide |
|||
| 33R-1835 | Fitzgerald | 100 ug | EUR 180 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of GJB6 antibody, catalog no. 70R-6097 |
|||
 FZD5 Blocking Peptide |
|||
| 33R-1836 | Fitzgerald | 100 ug | EUR 180 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of FZD5 antibody, catalog no. 70R-7475 |
|||
 ELMOD1 Blocking Peptide |
|||
| 33R-1837 | Fitzgerald | 100 ug | EUR 180 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of ELMOD1 antibody, catalog no. 70R-9490 |
|||
 C9ORF127 Blocking Peptide |
|||
| 33R-1838 | Fitzgerald | 100 ug | EUR 180 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of C9orf127 antibody, catalog no. 70R-7095 |
|||
 KIAA0692 Blocking Peptide |
|||
| 33R-1839 | Fitzgerald | 100 ug | EUR 180 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of KIAA0692 antibody, catalog no. 70R-3254 |
|||
 OR13C5 Blocking Peptide |
|||
| 33R-1840 | Fitzgerald | 100 ug | EUR 180 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of OR13C5 antibody, catalog no. 70R-7901 |
|||
 GINS2 Blocking Peptide |
|||
| 33R-1841 | Fitzgerald | 100 ug | EUR 180 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of GINS2 antibody, catalog no. 70R-5625 |
|||
 RGS16 Blocking Peptide |
|||
| 33R-1842 | Fitzgerald | 100 ug | EUR 180 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of RGS16 antibody, catalog no. 70R-1260 |
|||
 CACNB2 Blocking Peptide |
|||
| 33R-1843 | Fitzgerald | 100 ug | EUR 180 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of CACNB2 antibody, catalog no. 70R-5063 |
|||
 DNER Blocking Peptide |
|||
| 33R-1844 | Fitzgerald | 100 ug | EUR 180 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of DNER antibody, catalog no. 20R-1277 |
|||
 RFPL3 Blocking Peptide |
|||
| 33R-1845 | Fitzgerald | 100 ug | EUR 180 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of RFPL3 antibody, catalog no. 70R-1162 |
|||
 PENK Blocking Peptide |
|||
| 33R-1846 | Fitzgerald | 100 ug | EUR 180 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of PENK antibody, catalog no. 70R-6226 |
|||
 DGKQ Blocking Peptide |
|||
| 33R-1847 | Fitzgerald | 100 ug | EUR 180 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of DGKQ antibody, catalog no. 70R-9133 |
|||
 NUDC Blocking Peptide |
|||
| 33R-1848 | Fitzgerald | 100 ug | EUR 180 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of NUDC antibody, catalog no. 70R-5520 |
|||
 PABPC5 Blocking Peptide |
|||
| 33R-1849 | Fitzgerald | 100 ug | EUR 180 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of PABPC5 antibody, catalog no. 70R-4840 |
|||
 TRAF1 Blocking Peptide |
|||
| 33R-1850 | Fitzgerald | 100 ug | EUR 180 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of TRAF1 antibody, catalog no. 70R-10512 |
|||
 ZPLD1 Blocking Peptide |
|||
| 33R-1851 | Fitzgerald | 100 ug | EUR 180 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of ZPLD1 antibody, catalog no. 70R-7542 |
|||
 SREBF1 Blocking Peptide |
|||
| 33R-1852 | Fitzgerald | 100 ug | EUR 180 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of SREBF1 antibody, catalog no. 70R-10526 |
|||
 ATG4A Blocking Peptide |
|||
| 33R-1853 | Fitzgerald | 100 ug | EUR 180 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of ATG4A antibody, catalog no. 70R-2866 |
|||
 KRT14 Blocking Peptide |
|||
| 33R-1854 | Fitzgerald | 100 ug | EUR 180 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of KRT14 antibody, catalog no. 20R-1352 |
|||
 POLDIP3 Blocking Peptide |
|||
| 33R-1855 | Fitzgerald | 100 ug | EUR 180 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of POLDIP3 antibody, catalog no. 70R-4847 |
|||
 SRGAP1 Blocking Peptide |
|||
| 33R-1856 | Fitzgerald | 100 ug | EUR 180 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of SRGAP1 antibody, catalog no. 70R-9502 |
|||
 CYLC2 Blocking Peptide |
|||
| 33R-1857 | Fitzgerald | 100 ug | EUR 180 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of CYLC2 antibody, catalog no. 70R-2744 |
|||
 DKKL1 Blocking Peptide |
|||
| 33R-1858 | Fitzgerald | 100 ug | EUR 180 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of DKKL1 antibody, catalog no. 70R-7515 |
|||
 CHD1L Blocking Peptide |
|||
| 33R-1859 | Fitzgerald | 100 ug | EUR 180 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of CHD1L antibody, catalog no. 70R-1304 |
|||
 MYH9 Blocking Peptide |
|||
| 33R-1860 | Fitzgerald | 100 ug | EUR 180 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of MYH9 antibody, catalog no. 70R-2739 |
|||
 PTTG2 Blocking Peptide |
|||
| 33R-1861 | Fitzgerald | 100 ug | EUR 180 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of PTTG2 antibody, catalog no. 70R-8929 |
|||
 NFKBIE Blocking Peptide |
|||
| 33R-1862 | Fitzgerald | 100 ug | EUR 180 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of NFKBIE antibody, catalog no. 70R-8262 |
|||
 TMEM9 Blocking Peptide |
|||
| 33R-1863 | Fitzgerald | 100 ug | EUR 180 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of TMEM9 antibody, catalog no. 70R-7412 |
|||
 CAPS Blocking Peptide |
|||
| 33R-1864 | Fitzgerald | 100 ug | EUR 180 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of CAPS antibody, catalog no. 70R-5864 |
|||
 RAD54B Blocking Peptide |
|||
| 33R-1865 | Fitzgerald | 100 ug | EUR 180 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of RAD54B antibody, catalog no. 70R-5648 |
|||
 OASL Blocking Peptide |
|||
| 33R-1866 | Fitzgerald | 100 ug | EUR 180 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of OASL antibody, catalog no. 70R-5891 |
|||
 DMAP1 Blocking Peptide |
|||
| 33R-1867 | Fitzgerald | 100 ug | EUR 180 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of DMAP1 antibody, catalog no. 20R-1081 |
|||
 IGFALS Blocking Peptide |
|||
| 33R-1869 | Fitzgerald | 100 ug | EUR 180 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of IGFALS antibody, catalog no. 70R-6072 |
|||
 GPX3 Blocking Peptide |
|||
| 33R-1870 | Fitzgerald | 100 ug | EUR 180 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of GPX3 antibody, catalog no. 70R-5305 |
|||
 THG1L Blocking Peptide |
|||
| 33R-1871 | Fitzgerald | 100 ug | EUR 180 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of THG1L antibody, catalog no. 70R-3535 |
|||
 CCT5 Blocking Peptide |
|||
| 33R-1872 | Fitzgerald | 100 ug | EUR 180 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of CCT5 antibody, catalog no. 70R-3888 |
|||
 MBD2 Blocking Peptide |
|||
| 33R-1873 | Fitzgerald | 100 ug | EUR 180 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of MBD2 antibody, catalog no. 70R-1031 |
|||
|
KIF2B Blocking Peptide |
|||
| 33R-1874 | Fitzgerald | 100 ug | EUR 180 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of KIF2B antibody, catalog no. 70R-5604 |
|||
 NANOS1 Blocking Peptide |
|||
| 33R-1875 | Fitzgerald | 100 ug | EUR 180 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of NANOS1 antibody, catalog no. 70R-4987 |
|||
 ZNF280C Blocking Peptide |
|||
| 33R-1876 | Fitzgerald | 100 ug | EUR 180 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of ZNF280C antibody, catalog no. 70R-8333 |
|||
 Zfp161 Blocking Peptide |
|||
| 33R-1877 | Fitzgerald | 100 ug | EUR 180 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of Zfp161 antibody, catalog no. 70R-7991 |
|||
 SSR1 Blocking Peptide |
|||
| 33R-1878 | Fitzgerald | 100 ug | EUR 180 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of SSR1 antibody, catalog no. 70R-7311 |
|||
 LOC153222 Blocking Peptide |
|||
| 33R-1879 | Fitzgerald | 100 ug | EUR 180 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of LOC153222 antibody, catalog no. 70R-7905 |
|||
 ASB12 Blocking Peptide |
|||
| 33R-1880 | Fitzgerald | 100 ug | EUR 180 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of ASB12 antibody, catalog no. 70R-5841 |
|||
 NID2 Blocking Peptide |
|||
| 33R-1881 | Fitzgerald | 100 ug | EUR 180 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of NID2 antibody, catalog no. 70R-6064 |
|||
 ABCF3 Blocking Peptide |
|||
| 33R-1883 | Fitzgerald | 100 ug | EUR 180 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of ABCF3 antibody, catalog no. 70R-6278 |
|||
 SLC5A7 Blocking Peptide |
|||
| 33R-1884 | Fitzgerald | 100 ug | EUR 180 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of SLC5A7 antibody, catalog no. 70R-7211 |
|||
 HAO2 Blocking Peptide |
|||
| 33R-1885 | Fitzgerald | 100 ug | EUR 180 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of HAO2 antibody, catalog no. 70R-2913 |
|||
 Katna1 Blocking Peptide |
|||
| 33R-1887 | Fitzgerald | 100 ug | EUR 180 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of Katna1 antibody, catalog no. 70R-9162 |
|||
 C6ORF134 Blocking Peptide |
|||
| 33R-1888 | Fitzgerald | 100 ug | EUR 180 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of C6orf134 antibody, catalog no. 70R-3866 |
|||
 CPSF3 Blocking Peptide |
|||
| 33R-1889 | Fitzgerald | 100 ug | EUR 180 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of CPSF3 antibody, catalog no. 70R-1351 |
|||
 FBXO3 Blocking Peptide |
|||
| 33R-1890 | Fitzgerald | 100 ug | EUR 180 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of FBXO3 antibody, catalog no. 70R-2790 |
|||
 MPDZ Blocking Peptide |
|||
| 33R-1891 | Fitzgerald | 100 ug | EUR 180 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of MPDZ antibody, catalog no. 70R-2266 |
|||
 ARHGDIG Blocking Peptide |
|||
| 33R-1892 | Fitzgerald | 100 ug | EUR 180 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of ARHGDIG antibody, catalog no. 70R-6038 |
|||
 PDXDC1 Blocking Peptide |
|||
| 33R-1893 | Fitzgerald | 100 ug | EUR 180 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of PDXDC1 antibody, catalog no. 70R-4233 |
|||
 LDLRAD1 Blocking Peptide |
|||
| 33R-1894 | Fitzgerald | 100 ug | EUR 180 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of LDLRAD1 antibody, catalog no. 70R-6670 |
|||
 TAF7L Blocking Peptide |
|||
| 33R-1895 | Fitzgerald | 100 ug | EUR 180 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of TAF7L antibody, catalog no. 20R-1157 |
|||
 POLR3GL Blocking Peptide |
|||
| 33R-1896 | Fitzgerald | 100 ug | EUR 180 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of POLR3GL antibody, catalog no. 70R-10078 |
|||
 LDLRAD3 Blocking Peptide |
|||
| 33R-1897 | Fitzgerald | 100 ug | EUR 180 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of LDLRAD3 antibody, catalog no. 70R-9224 |
|||
 ZGPAT Blocking Peptide |
|||
| 33R-1898 | Fitzgerald | 100 ug | EUR 180 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of ZGPAT antibody, catalog no. 70R-3509 |
|||
 Mcm10 Blocking Peptide |
|||
| 33R-1899 | Fitzgerald | 100 ug | EUR 180 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of Mcm10 antibody, catalog no. 70R-8186 |
|||
 HSPA1L Blocking Peptide |
|||
| 33R-1900 | Fitzgerald | 100 ug | EUR 180 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of HSPA1L antibody, catalog no. 70R-4431 |
|||
 SNRPN Blocking Peptide |
|||
| 33R-1901 | Fitzgerald | 100 ug | EUR 180 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of SNRPN antibody, catalog no. 70R-8478 |
|||
 DHRSX Blocking Peptide |
|||
| 33R-1902 | Fitzgerald | 100 ug | EUR 180 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of DHRSX antibody, catalog no. 70R-7875 |
|||
 TTC33 Blocking Peptide |
|||
| 33R-1903 | Fitzgerald | 100 ug | EUR 180 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of TTC33 antibody, catalog no. 70R-3754 |
|||
 CTAGE5 Blocking Peptide |
|||
| 33R-1904 | Fitzgerald | 100 ug | EUR 180 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of CTAGE5 antibody, catalog no. 70R-7102 |
|||
 CPEB4 Blocking Peptide |
|||
| 33R-1905 | Fitzgerald | 100 ug | EUR 180 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of CPEB4 antibody, catalog no. 70R-4969 |
|||
 FSIP1 Blocking Peptide |
|||
| 33R-1906 | Fitzgerald | 100 ug | EUR 180 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of FSIP1 antibody, catalog no. 70R-3397 |
|||
 DDX27 Blocking Peptide |
|||
| 33R-1907 | Fitzgerald | 100 ug | EUR 180 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of DDX27 antibody, catalog no. 70R-1385 |
|||
 ADD3 Blocking Peptide |
|||
| 33R-1908 | Fitzgerald | 100 ug | EUR 180 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of ADD3 antibody, catalog no. 70R-9940 |
|||
 C22ORF30 Blocking Peptide |
|||
| 33R-1909 | Fitzgerald | 100 ug | EUR 180 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of C22orf30 antibody, catalog no. 70R-4259 |
|||
 CHGN Blocking Peptide |
|||
| 33R-1910 | Fitzgerald | 100 ug | EUR 180 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of ChGn antibody, catalog no. 70R-6125 |
|||
 EIF2S2 Blocking Peptide |
|||
| 33R-1911 | Fitzgerald | 100 ug | EUR 180 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of EIF2S2 antibody, catalog no. 70R-4904 |
|||
 OAS2 Blocking Peptide |
|||
| 33R-1912 | Fitzgerald | 100 ug | EUR 180 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of OAS2 antibody, catalog no. 70R-5885 |
|||
 Glycoprotein Blocking Peptide |
|||
| 33R-1913 | Fitzgerald | 100 ug | EUR 180 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of GPNMB antibody, catalog no. 70R-7234 |
|||
 MSH5 Blocking Peptide |
|||
| 33R-1915 | Fitzgerald | 100 ug | EUR 180 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of MSH5 antibody, catalog no. 70R-5579 |
|||
 DDX19B Blocking Peptide |
|||
| 33R-1916 | Fitzgerald | 100 ug | EUR 180 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of DDX19B antibody, catalog no. 70R-1379 |
|||
 PDS5B Blocking Peptide |
|||
| 33R-1917 | Fitzgerald | 100 ug | EUR 180 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of PDS5B antibody, catalog no. 70R-2864 |
|||